Country for PR: United States
Contributor: PR Newswire New York
Thursday, August 06 2020 - 22:10
Caprion-HistoGeneX and Viroclinics-DDL announce a strategic partnership to offer integrated, complementary services to advance infectious disease research and COVID-19 therapeutic development
MONTREAL and ROTTERDAM, Netherlands, Aug. 7, 2020 /PRNewswire-AsiaNet/ --

-- Caprion-HistoGeneX, a specialized CRO providing immunology, proteomics, 
histopathology and genomics services, and Viroclinics-DDL, a provider of 
preclinical and clinical trial services for vaccine, antiviral, and diagnostic 
development, are pleased to announce a new partnership that will offer global, 
integrated services to support discovery and development of vaccines and 
antiviral therapies.

Caprion-HistoGeneX and Viroclinics-DDL announced today a new strategic 
partnership to expand their global capabilities addressing the emerging needs 
for therapeutic and prophylactic solutions to target infectious diseases 
including COVID-19. This partnership brings together the leadership of two 
prominent contract research organizations serving the pharmaceutical and 
biotechnology community with specialized assays and technologies relevant to 
clinical and preclinical studies aimed at developing vaccines and other 
therapies for infectious diseases.

Logo – 

Logo - 

By combining their respective expertise, the two companies offer a full suite 
of specialized services to support vaccine and antiviral studies along with a 
broad global presence, including sites in The Netherlands, Canada, USA, 
Belgium, UK, Australia, and China. 
"We are excited to partner with Caprion-HistoGeneX and combine the unique 
strengths of our companies to deliver first class contract research services to 
our customers developing innovative modalities to combat infectious diseases." 
said Davide Molho DVM, the new CEO of Viroclinics-DDL. 

The partnership allows for a seamless, integrated service experience for 
customers worldwide, with a broad service offering covering all stages of 
vaccine and antiviral development, ranging from preclinical and in-vitro 
research models to the deployment of custom-developed and off-the-shelf 
functional assays for monitoring vaccine efficacy. In addition to leveraging a 
broad selection of specialized platforms such as viral neutralization, flow 
cytometry, ELISpot and immuno-assays, the partnership will also provide access 
to an extended global network of clinical sample processing facilities across 
North America, South America, Europe, Africa and Asia, along with operational 
and logistical services including sample management and sampling kits. 

"With our complementary competencies, we are able to fulfill the R&D and 
clinical outsourcing needs of the market. In the wake of the current COVID-19 
pandemic, we believe that this joint initiative will bring vaccine and 
antiviral testing to the next level." said Martin LeBlanc, CEO of 

About Caprion Biosciences Inc. 
Caprion - HistoGeneX is a leading provider of specialized precision medicine 
services to the biopharmaceutical industry including flow and mass cytometry 
immune monitoring, quantitative mass spectrometry, molecular profiling, as well 
as quantitative immunohistochemistry. Leveraging its integrated platforms, 
Caprion-HistoGeneX supports the entire drug development cycle, from discovery 
to clinical trials. The company operates globally with laboratories located in 
Canada, USA, Belgium, UK, Australia, and China. 
For more information: and 

About Viroclinics-DDL 
Viroclinics-DDL is a global leading virology contract research organization, 
serving the biopharmaceutical community with a broad range of preclinical 
research, clinical diagnostic, assay development and clinical trial logistic 
services. Viroclinics' extensive experience with clinical and preclinical 
studies for viruses, including its specialty in respiratory viruses, puts the 
company at the forefront in supporting the development of vaccines, antibodies 
and antiviral compounds targeting viral infectious diseases. Our in-house state 
of the art preclinical and clinical BSL-2 and BSL-3 laboratories allow for 
complex experiments with highly pathogenic organisms. Viroclinics is based in 
Rotterdam, Rijswijk, Schaijk, (The Netherlands) and employs more than 270 
well-trained, dedicated scientists and technical experts. For more information: and

Media Contact: Viroclinics-DDL, Sander Verkerk, Manager Marketing & 
Communication, Viroclinics-DDL,; Media Contact: 
Caprion Biosciences Inc., Guylaine Galipeau, Global Marketing Director, Caprion 
Biosciences Inc.,

Source - Caprion Biosciences